Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
A.P. Pharma, Inc.
A.P. Pharma Announces Fourth Quarter and Year-End 2008 Financial Results and Provides Update on APF530 NDA
April 17th, 2009
A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, reported financial results for its fourth quarter and full year ended December 31, 2008. In addition, the Company provided an update on the status of its new drug application (NDA) for APF530. APF530, the Company's proprietary, sustained-release formulation of granisetron, is being developed for the prevention of chemotherapy-induced nausea and vomiting (CINV). The Company is in the final stages of preparing its submission and expects to file the NDA with the U.S. Food and Drug Administration (FDA) during the second quarter of 2009. The Company also continues to pursue corporate partnering opportunities for APF530....
Source: Health Business Week (2009-04-17)
|
|
Advertisement |
 |
- 141 Capital, Inc. Positioned for Continued Success in the Trading Arena
- Bankruptcy Court Judge Grants All First-Day Motions in 1800mattress.com Chapter 11 Proceeding
- BBC World News Joins the 1Cast Network
- Music from the Motion Picture 'The Lifting of the Veil' Is Officially Released on iTunes and Other Online Stores by 2 Republic Music Group, Which Is Operated by the 20-Year-Old South Asian Music Mogul C
- 24-7StockAlert.net is Pleased to Offer an Explosive Stock Alerts Service
- 24-7StockAlert.net Offers Hot Stock Alert on Today's Largest Percentage Movers - ACOR, FSLR, NOK, C, BAC, GOOG, AMLN, APOL, JPM, IBM C
|
 |
|
|
|
